FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies
Acting FDA Commissioner Andrew von Eschenbach stressed his commitment to improving agency morale during his confirmation hearing
More from Archive
More from Medtech Insight
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
• By
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.